Published Technical Disclosure Archive

Multimodal Chromatography Method for HIV-1 Envelope Glycoprotein Purification in Specialized Environments

Publication ID: 24-11857619_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Multimodal Chromatography Method for HIV-1 Envelope Glycoprotein Purification in Specialized Environments,” Published Technical Disclosure No. 24-11857619_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857619_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,619.

Summary of the Inventive Concept

An advanced multimodal chromatography method for purifying HIV-1 envelope glycoprotein tailored for high-security laboratories, disaster relief, extreme weather conditions, high-security needs, and remote, resource-limited areas.

Background and Problem Solved

The original patent disclosed a multimodal chromatography method for purifying HIV-1 envelope glycoprotein. However, this method lacks adaptability for specific, narrow markets or unique operational environments. The new inventive concept addresses this limitation by providing specialized variations and niche solutions for high-security laboratories, disaster relief, extreme weather conditions, high-security needs, and remote, resource-limited areas.

Detailed Description of the Inventive Concept

The new inventive concept comprises a multimodal chromatography method for purifying HIV-1 envelope glycoprotein in various specialized environments. For high-security laboratories, the method involves using a secure, tamper-evident container. For disaster relief, a portable multimodal chromatography device is housed in a secure, weather-resistant enclosure. In extreme weather conditions, the method employs a weather-resistant container. For high-security needs, the method incorporates a secure, biometric-authentication system for controlling access to the device. In remote, resource-limited areas, the method utilizes a portable, solar-powered device.

Novelty and Inventive Step

The new inventive concept's novelty lies in its adaptability for specific, narrow markets or unique operational environments, which is not addressed by the original patent. The inventive step involves the integration of specialized components and features to ensure the multimodal chromatography method's effectiveness in these environments.

Alternative Embodiments and Variations

Other ways the inventive concept could be implemented include using different types of secure containers or enclosures, incorporating additional security features, or adapting the method for use in other specialized environments such as space exploration or military operations.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in industries such as biotechnology, pharmaceuticals, and healthcare, particularly in areas requiring high-security, disaster relief, or operation in extreme weather conditions. The target market includes research institutions, pharmaceutical companies, and government agencies involved in HIV-1 research and treatment.

CPC Classifications

SectionClassGroup
A A61 A61K39/21
C C07 C07K1/18
C C07 C07K14/005
C C07 C07K14/162
C C12 C12N7/02
A A61 A61K2039/53
C C12 C12N2740/16051
C C12 C12N2740/16111
C C12 C12N2740/16122
C C12 C12N2740/16134

Field of Art

Biotechnology and protein purification, specifically focused on HIV envelope glycoprotein isolation techniques, requiring advanced knowledge of chromatography, protein chemistry, and molecular biology

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with a PhD in biotechnology or molecular biology, expertise in protein purification techniques, familiarity with multimodal chromatography, and understanding of HIV protein structural characteristics

Obviousness Rationale

A person having ordinary skill would recognize that the core multimodal chromatography method remains fundamentally unchanged, with the PTD merely adding contextual adaptations for specific environmental conditions. The fundamental protein capture and purification process follows the source patent's core methodology, with the variations representing predictable engineering solutions to extend the technique's applicability. These environmental modifications represent standard design adaptations that would be obvious to a skilled practitioner seeking to implement the purification method in diverse operational contexts.

Obvious Combinations & Variations

Source Patent Element
Multimodal resin-based HIV-1 gp140 protein capture method
PTD Variation
Incorporating secure, tamper-evident container for high-security laboratory environments
Obviousness Reasoning
Adding security features to a scientific instrument represents a predictable design modification for sensitive biological materials, using standard containment techniques known in laboratory safety protocols
Source Patent Element
HIV-1 envelope glycoprotein purification process
PTD Variation
Developing portable, solar-powered device for resource-limited areas
Obviousness Reasoning
Adapting laboratory techniques to portable, power-independent configurations is a standard engineering approach for extending technological capabilities to challenging environments
Source Patent Element
Multimodal chromatography technique for protein isolation
PTD Variation
Implementing biometric authentication for device access control
Obviousness Reasoning
Integrating security mechanisms into scientific instrumentation represents a predictable solution for protecting sensitive research materials and processes
Source Patent Element
HIV-1 gp140 protein purification method
PTD Variation
Weather-resistant containment for extreme environmental conditions
Obviousness Reasoning
Protecting scientific equipment from environmental challenges is a routine engineering design consideration with well-established technological solutions
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed in the Published Technical Disclosure would be considered obvious extensions of US Patent 11857619, as they represent predictable adaptations of the fundamental multimodal chromatography method for HIV-1 envelope glycoprotein purification, employing standard engineering modifications to address specific operational environments without introducing non-obvious technological innovations.

Original Patent Information

Patent NumberUS 11,857,619
TitleMultimodal chromatography method for the purification of HIV-1 envelope glycoprotein
Assignee(s)Janssen Vaccines & Prevention B.V.